Han Sang-cheol, the eldest son of Han Seung-soo, chairman of JEIL PHARMACEUTICAL, has been appointed as co-CEO. Accordingly, JEIL PHARMACEUTICAL has transitioned to a co-CEO system with Chief Executive Officer Seong Seok-je and Co-CEO Han Sang-cheol.
JEIL PHARMACEUTICAL held a board meeting on the 25th and noted the appointment of Han Sang-cheol as co-CEO. Han is the grandson of the late Han Won-seok, the founder of JEIL PHARMACEUTICAL, and the eldest son of Chairman Han Seung-soo. He graduated from Yonsei University with a degree in industrial engineering and from the University of Rochester graduate school with a degree in business administration, and joined JEIL PHARMACEUTICAL in 2006 as a Director General. He had previously served as the executive director of marketing, executive director of management planning, and vice president before becoming president of JEIL PHARMACEUTICAL in 2023.
Since 2017, he has also held the position of representative in the holding company JEIL PHARMA HOLDINGS. Han has been recognized for contributing to the company's growth and development by passing through key positions necessary for management while pushing for a focus on research and development of new drugs, business diversification, and the discovery of new businesses. The company stated that under Han’s leadership, its subsidiary Onconic Therapeutics, established in 2020 for research and development of new drugs, obtained approval last year for the gastroesophageal reflux disease treatment 'Jackubogen' as the 37th new drug in South Korea, marking a significant turning point in improving the structure of JEIL PHARMACEUTICAL, which had previously focused on sales of commercial products.
A spokesperson for JEIL PHARMACEUTICAL said, 'While maximizing the expertise of the co-CEOs, responsibility management for enhancing corporate competitiveness will be strengthened.'